Please assess the completion status of the following clinical trial:

Trial Title: Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster Vaccines

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Healthy Individuals who received full vaccination with any authorized COVID-19 vaccine and decided to receive a booster vaccination as recommended by national guidelines. -~Exclusion Criteria:~1. Presence of diseases or therapies that are likely to interfere with the immune response to booster vaccination.~2. Any contraindications to the vaccine planned to receive as listed in the product characteristics.~3. Lack of willingness to undergo serial blood draws and attend follow-up appointments.~4. Having already received a third (booster) vaccination with any COVID-19 vaccine.~5. Women who are pregnant or breastfeeding.~6. Persons who are not willing to sign the informed consents (biobank informed consent and study specific informed consent) -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- blood and saliva sampling (Type: None): blood and saliva samples will be taken

Based on this trial design, predict the completion outcome and termination type (if applicable).